Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Updated Phase 1 Results of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Relapsed and/or Refractory Multiple Myeloma (RRMM)

Alfred L. Garfall, MD, Saad Z. Usmani, MDMBBS,MBA, María-Victoria Mateos, Hareth Nahi, MD PhD, Niels W.C.J. van de Donk, MD PhD, Jesus F. San-Miguel, MD PhD, Albert Oriol Rocafiguera, MD, Laura Rosinol, MD PhD, Ajai Chari, MD, Manisha Bhutani, MD, Lixia Pei, PhD, Raluca Verona, PhD, Suzette Girgis, PhD BPharm, MS, Tara Stephenson, PhD, Jenna D. Goldberg, MD, Arnob Banerjee, MD, Amrita Krishnan, MD

Blood (2020) 136 (Supplement 1): 27.

https://doi.org/10.1182/blood-2020-138831

Published: 2020

Journal Articles

Skeletal Muscle Density Is Independently Prognostic of Outcomes in Newly Diagnosed Mantle Cell Lymphoma Patients: Post Hoc Analysis of LYM 3002

Michael P. Chu, MD, Andrew Belch, MD, Lixia Pei, PhD, Xue (Loya) Yang, PhD, Tadeusz Robak, MD PhD, Brendan Rooney, PhD, Andrew Cakana, MD, Helgi van de Velde, MD PhD, Michael B Sawyer, MD

Blood (2015) 126 (23): 1477.

https://doi.org/10.1182/blood.V126.23.1477.1477

Published: 2015

Journal Articles

Efficacy and Safety of Bortezomib Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (VR-CAP) Vs R-CHOP in Japanese Patients (Pts) with Newly Diagnosed Mantle Cell Lymphoma (MCL) Not Considered for Transplantation Enrolled in the International, Randomized, Phase 3 LYM-3002 Study (NCT00722137)

Michinori Ogura, MD PhD, Lixia Pei, PhD, Brendan Rooney, PhD, Helgi van de Velde, MD PhD, Franco Cavalli, MD for the LYM-3002 investigators

Blood (2014) 124 (21): 3061.

https://doi.org/10.1182/blood.V124.21.3061.3061

Published: 2014

Journal Articles

Efficacy and Safety of Frontline Bortezomib, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (VR-CAP) Vs R-CHOP in a Subset of Newly Diagnosed Mantle Cell Lymphoma (MCL) Patients (Pts) Medically Eligible for Transplantation in the Randomized Phase 3 LYM-3002 Study (NCT00722137)

Johannes Drach, MD, Huiqiang Huang, MD, Olga S Samoilova, MD, Andrew Belch, MD, Charles M. Farber, MD PhD, André Bosly, MD PhD, Jan Novak, MD PhD, Jan Zaucha, MD PhD, Angela Dascalescu, MD PhD, Udomsak Bunworasate, MD, Zvenyslava Masliak, MD PhD, Kateryna Vilchevskaya, MD PhD, Tadeusz Robak, MD, Lixia Pei, PhD, Brendan Rooney, PhD, Helgi van de Velde, MD PhD, Franco Cavalli, MD

Blood (2014) 124 (21): 3064.

https://doi.org/10.1182/blood.V124.21.3064.3064

Published: 2014

Journal Articles

Bortezomib (Btz) Dose Intensity Is the Strongest Predictor for Overall Survival (OS) in Mantle Cell Lymphoma (MCL) Patients (Pts) Not Considered for Transplantation, Receiving Frontline Btz Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (VR-CAP) Therapy in the Phase 3 LYM-3002 Study

Tadeusz Robak, MD, Huiqiang Huang, MD, Jie Jin, MD, Jun Zhu, MD, Ting Liu, Olga S Samoilova, MD, Halyna Pylypenko, MD, Gregor Verhoef, MD PhD, Noppadol Siritanaratkul, MD, Evgenii A Osmanov, MD PhD, Julia Alexeeva, MD PhD, Juliana Pereira, PhD, Jiri Mayer, Prof., MD PhD, Xiaonan Hong, MD, Yoshiharu Maeda, MD, Lixia Pei, PhD, Brendan Rooney, PhD, Helgi van de Velde, MD PhD, Franco Cavalli, MD

Blood (2014) 124 (21): 4412.

https://doi.org/10.1182/blood.V124.21.4412.4412

Published: 2014

NARROW

Updated Phase 1 Results of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Relapsed and/or Refractory Multiple Myeloma (RRMM)

Skeletal Muscle Density Is Independently Prognostic of Outcomes in Newly Diagnosed Mantle Cell Lymphoma Patients: Post Hoc Analysis of LYM 3002

Efficacy and Safety of Frontline Bortezomib, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (VR-CAP) Vs R-CHOP in a Subset of Newly Diagnosed Mantle Cell Lymphoma (MCL) Patients (Pts) Medically Eligible for Transplantation in the Randomized Phase 3 LYM-3002 Study (NCT00722137)

Bortezomib (Btz) Dose Intensity Is the Strongest Predictor for Overall Survival (OS) in Mantle Cell Lymphoma (MCL) Patients (Pts) Not Considered for Transplantation, Receiving Frontline Btz Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (VR-CAP) Therapy in the Phase 3 LYM-3002 Study

Email alerts

ASH Publications

American Society of Hematology

Updated Phase 1 Results of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Relapsed and/or Refractory Multiple Myeloma (RRMM)

Skeletal Muscle Density Is Independently Prognostic of Outcomes in Newly Diagnosed Mantle Cell Lymphoma Patients: Post Hoc Analysis of LYM 3002

Efficacy and Safety of Frontline Bortezomib, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (VR-CAP) Vs R-CHOP in a Subset of Newly Diagnosed Mantle Cell Lymphoma (MCL) Patients (Pts) Medically Eligible for Transplantation in the Randomized Phase 3 LYM-3002 Study (NCT00722137)

Bortezomib (Btz) Dose Intensity Is the Strongest Predictor for Overall Survival (OS) in Mantle Cell Lymphoma (MCL) Patients (Pts) Not Considered for Transplantation, Receiving Frontline Btz Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (VR-CAP) Therapy in the Phase 3 LYM-3002 Study

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only